On June 12, AstraZeneca and Eli Lilly terminated their two Phase III clinical...
- Another BACE inhibitor fails in phase III trials
- Deals this week: InSphero, Ind-Swift Laboratories, Sage Therapeutics
- Deals this week: Deciphera Pharmaceuticals, Tricida, ENYO Pharma
- M&As this week: Tongyang, Glenmark Pharmaceuticals, Leerink Revelation Partners
- Deals this week: HitGen, Lion TCR, Information Medical
Another BACE inhibitor fails in phase III trials
On June 12, AstraZeneca and Eli Lilly terminated their two Phase III clinical trials of oral amyloid targeting β-secretase (BACE) inhibitor lanabecestat in Alzheimer’s disease (AD). The partners made the decision to terminate AMARANTH (NCT02245737) and the DAYBREAK-ALZ (NCT02783573) trials after an independent data monitoring committee concluded they were unlikely to meet primary endpoints based on interim analysis. The related AMARANTH extension trial (NCT02972658) will also be discontinued. This termination is preceded by recent failures of BACE inhibitors in late stage clinical development for the treatment of AD.
Laser Microdissection with PALM MicroBeam Technology
Its laser microdissection with PALM MicroBeam technology allows for contact-free and uncontaminated specimen collection from specific compartments of skin and hair follicles for use in next-generation sequencing analysis.
Zepatier for the Treatment of Chronic Hepatitis C GT1 and GT4 Infection
Zepatier is a once-daily, oral selective combination of nonstructural 5A (NS5A) replication complex inhibitor elbasvir (50mg) and non-structural 3/4A protease inhibitor grazoprevir (100mg).
Deals this week: InSphero, Ind-Swift Laboratories, Sage Therapeutics
InSphero has raised $10m in a funding round provided by internal and external investors.
Afinitor Disperz (everolimus) for the Treatment of TSC-Associated Partial-Onset Seizures
Afinitor Disperz® (everolimus) is indicated for the treatment of tuberous sclerosis complex (TSC) associated partial-onset seizures in adult and paediatric patients.
State-of-the-art Skin and Hair Research Preclinical and Clinical Services
Monsterium Laboratory's Laser Capture Microdissection service utilises PALM MicroBeam technology for uncontaminated specimen collection from specific compartments of skin and hair follicles for ribonucleic acid (RNA), DNA and protein isolation.
M&As this week: Madison Dearborn Partners, Versartis
Madison Dearborn Partners (MDP) has reached an agreement to purchase a majority interest in Alcami Corp from asset management firm Ares Capital Corp.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.